These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1334824)
1. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model. Gordon YJ; Romanowski E; Araullo-Cruz T; De Clercq E Cornea; 1992 Nov; 11(6):529-33. PubMed ID: 1334824 [TBL] [Abstract][Full Text] [Related]
2. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Gordon YJ; Romanowski EG; Araullo-Cruz T Invest Ophthalmol Vis Sci; 1994 Nov; 35(12):4135-43. PubMed ID: 7960596 [TBL] [Abstract][Full Text] [Related]
3. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Romanowski EG; Yates KA; Gordon YJ Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. de Oliveira CB; Stevenson D; LaBree L; McDonnell PJ; Trousdale MD Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201 [TBL] [Abstract][Full Text] [Related]
5. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Romanowski EG; Yates KA; Teuchner B; Nagl M; Irschick EU; Gordon YJ Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011 [TBL] [Abstract][Full Text] [Related]
6. An ocular model of adenovirus type 5 infection in the NZ rabbit. Gordon YJ; Romanowski E; Araullo-Cruz T Invest Ophthalmol Vis Sci; 1992 Mar; 33(3):574-80. PubMed ID: 1312070 [TBL] [Abstract][Full Text] [Related]
7. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model. Romanowski EG; Gordon YJ Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):158-62. PubMed ID: 11133861 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Romanowski EG; Gordon YJ Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476 [TBL] [Abstract][Full Text] [Related]
9. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Kaneko H; Mori S; Suzuki O; Iida T; Shigeta S; Abe M; Ohno S; Aoki K; Suzutani T Antiviral Res; 2004 Jan; 61(1):63-6. PubMed ID: 14670595 [TBL] [Abstract][Full Text] [Related]
10. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Romanowski EG; Bartels SP; Gordon YJ Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596 [TBL] [Abstract][Full Text] [Related]
11. An ocular model of Adenovirus type 5 infection in the rabbit. De Hauwere B; Lutz A; Maudgal PC; Neyts J; de Clercq E Bull Soc Belge Ophtalmol; 1995; 259():33-42. PubMed ID: 8936772 [TBL] [Abstract][Full Text] [Related]
12. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Romanowski EG; Araullo-Cruz T; Gordon YJ Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458 [TBL] [Abstract][Full Text] [Related]
14. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model. Gordon YJ; Romanowski EG; Araullo-Cruz T Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711 [TBL] [Abstract][Full Text] [Related]
15. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820 [TBL] [Abstract][Full Text] [Related]
16. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446 [TBL] [Abstract][Full Text] [Related]
17. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R Arch Ophthalmol; 2001 Oct; 119(10):1487-91. PubMed ID: 11594949 [TBL] [Abstract][Full Text] [Related]
18. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R Ophthalmology; 2002 May; 109(5):845-50. PubMed ID: 11986086 [TBL] [Abstract][Full Text] [Related]
19. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Romanowski EG; Yates KA; Gordon YJ Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5295-9. PubMed ID: 19516011 [TBL] [Abstract][Full Text] [Related]